Bridgefront Capital, LLC Apellis Pharmaceuticals, Inc. Transaction History

Bridgefront Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $98,738 - $372,493	4,175 Added 158.93%	6,802 $258,000
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $201,438 - $245,125	2,627 New	2,627 $239,000
Q3 2021 Nov 12, 2021	SELL	$31.4 - $69.84 $106,446 - $236,757	-3,390 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$40.9 - $64.9 $52,720 - $83,656	-1,289 Reduced 27.55%	3,390 $214,000
Q1 2021 May 17, 2021	BUY	$40.8 - $57.39 $190,903 - $268,527	4,679 New	4,679 $201,000

300

111M

2.63M

845K

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.67B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgefront Capital, LLC with notifications on news.